APO Research
Talk to an analyst

APO RESEARCH · REPORT

Attention-Deficit Hyperactivity Disorder Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Attention-Deficit Hyperactivity Disorder Treatment Market Outlook and Growth Opportunities 2026

27 December 2025193 pages

Choose your research edition.

Industry ResearchAttention-Deficit Hyperactivity Disorder Treatment Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Attention-Deficit Hyperactivity Disorder Treatment Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Attention-Deficit Hyperactivity Disorder Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Attention-Deficit Hyperactivity Disorder Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Attention-Deficit Hyperactivity Disorder Treatment Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Attention-Deficit Hyperactivity Disorder Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Attention-Deficit Hyperactivity Disorder Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Attention-Deficit Hyperactivity Disorder Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Attention-Deficit Hyperactivity Disorder Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Attention-Deficit Hyperactivity Disorder Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Attention-Deficit Hyperactivity Disorder Treatment market include The Takeda Pharmaceutical Company Limited, Johnson & Johnson, Eli Lilly and Company, Pfizer Inc., Supernus Pharmaceutical,Inc., purdue Pharma L.P., Novartis AG, Neos Therapeutics Inc. and Mallinckrodt Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Attention-Deficit Hyperactivity Disorder Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Attention-Deficit Hyperactivity Disorder Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Attention-Deficit Hyperactivity Disorder Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Attention-Deficit Hyperactivity Disorder Treatment market.

Attention-Deficit Hyperactivity Disorder Treatment Segment by Company

The Takeda Pharmaceutical Company Limited

Johnson & Johnson

Eli Lilly and Company

Pfizer Inc.

Supernus Pharmaceutical,Inc.

purdue Pharma L.P.

Novartis AG

Neos Therapeutics Inc.

Mallinckrodt Pharmaceuticals

Lupin Limited

Attention-Deficit Hyperactivity Disorder Treatment Segment by Type

Stimulants

Non-stimulants

Attention-Deficit Hyperactivity Disorder Treatment Segment by Application

Hospital

Clinic

Others

Attention-Deficit Hyperactivity Disorder Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Attention-Deficit Hyperactivity Disorder Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Attention-Deficit Hyperactivity Disorder Treatment key companies, revenue, market share, and recent developments.

3. To split the Attention-Deficit Hyperactivity Disorder Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Attention-Deficit Hyperactivity Disorder Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Attention-Deficit Hyperactivity Disorder Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Attention-Deficit Hyperactivity Disorder Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attention-Deficit Hyperactivity Disorder Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Attention-Deficit Hyperactivity Disorder Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attention-Deficit Hyperactivity Disorder Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Attention-Deficit Hyperactivity Disorder Treatment industry.

Chapter 3: Detailed analysis of Attention-Deficit Hyperactivity Disorder Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Attention-Deficit Hyperactivity Disorder Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Attention-Deficit Hyperactivity Disorder Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Attention-Deficit Hyperactivity Disorder Treatment Industry Trends Table 2. Attention-Deficit Hyperactivity Disorder Treatment Industry Drivers Table 3. Attention-Deficit Hyperactivity Disorder Treatment Industry Opportunities and Challenges Table 4. Attention-Deficit Hyperactivity Disorder Treatment Industry Restraints Table 5. Global Attention-Deficit Hyperactivity Disorder Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Attention-Deficit Hyperactivity Disorder Treatment Revenue Share by Company (2021-2026) Table 7. Global Attention-Deficit Hyperactivity Disorder Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Attention-Deficit Hyperactivity Disorder Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Attention-Deficit Hyperactivity Disorder Treatment Company, Product Type & Application Table 10. Global Attention-Deficit Hyperactivity Disorder Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Attention-Deficit Hyperactivity Disorder Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Stimulants Table 15. Significant Companies of Non-stimulants Table 16. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type (2021-2026) Table 20. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Others Table 24. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application (2021-2026) Table 28. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application (2027-2032) Table 29. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Region (2021-2026) Table 32. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Region (2027-2032) Table 34. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Market Share by Country (2021-2026) Table 37. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Market Share by Country (2027-2032) Table 39. The Takeda Pharmaceutical Company Limited Company Information Table 40. The Takeda Pharmaceutical Company Limited Business Overview Table 41. The Takeda Pharmaceutical Company Limited Attention-Deficit Hyperactivity Disorder Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. The Takeda Pharmaceutical Company Limited Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio Table 43. The Takeda Pharmaceutical Company Limited Recent Development Table 44. Johnson & Johnson Company Information Table 45. Johnson & Johnson Business Overview Table 46. Johnson & Johnson Attention-Deficit Hyperactivity Disorder Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Johnson & Johnson Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio Table 48. Johnson & Johnson Recent Development Table 49. Eli Lilly and Company Company Information Table 50. Eli Lilly and Company Business Overview Table 51. Eli Lilly and Company Attention-Deficit Hyperactivity Disorder Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Eli Lilly and Company Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio Table 53. Eli Lilly and Company Recent Development Table 54. Pfizer Inc. Company Information Table 55. Pfizer Inc. Business Overview Table 56. Pfizer Inc. Attention-Deficit Hyperactivity Disorder Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Pfizer Inc. Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio Table 58. Pfizer Inc. Recent Development Table 59. Supernus Pharmaceutical,Inc. Company Information Table 60. Supernus Pharmaceutical,Inc. Business Overview Table 61. Supernus Pharmaceutical,Inc. Attention-Deficit Hyperactivity Disorder Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Supernus Pharmaceutical,Inc. Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio Table 63. Supernus Pharmaceutical,Inc. Recent Development Table 64. purdue Pharma L.P. Company Information Table 65. purdue Pharma L.P. Business Overview Table 66. purdue Pharma L.P. Attention-Deficit Hyperactivity Disorder Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. purdue Pharma L.P. Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio Table 68. purdue Pharma L.P. Recent Development Table 69. Novartis AG Company Information Table 70. Novartis AG Business Overview Table 71. Novartis AG Attention-Deficit Hyperactivity Disorder Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Novartis AG Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio Table 73. Novartis AG Recent Development Table 74. Neos Therapeutics Inc. Company Information Table 75. Neos Therapeutics Inc. Business Overview Table 76. Neos Therapeutics Inc. Attention-Deficit Hyperactivity Disorder Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Neos Therapeutics Inc. Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio Table 78. Neos Therapeutics Inc. Recent Development Table 79. Mallinckrodt Pharmaceuticals Company Information Table 80. Mallinckrodt Pharmaceuticals Business Overview Table 81. Mallinckrodt Pharmaceuticals Attention-Deficit Hyperactivity Disorder Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Mallinckrodt Pharmaceuticals Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio Table 83. Mallinckrodt Pharmaceuticals Recent Development Table 84. Lupin Limited Company Information Table 85. Lupin Limited Business Overview Table 86. Lupin Limited Attention-Deficit Hyperactivity Disorder Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Lupin Limited Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio Table 88. Lupin Limited Recent Development Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Attention-Deficit Hyperactivity Disorder Treatment Product Image Figure 2. Global Attention-Deficit Hyperactivity Disorder Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Attention-Deficit Hyperactivity Disorder Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Attention-Deficit Hyperactivity Disorder Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Stimulants Image Figure 8. Non-stimulants Image Figure 9. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Others Image Figure 15. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application (2021-2032) Figure 18. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Attention-Deficit Hyperactivity Disorder Treatment Sales Value (2021-2032) & (US$ Million) Figure 21. North America Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Attention-Deficit Hyperactivity Disorder Treatment Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Attention-Deficit Hyperactivity Disorder Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Attention-Deficit Hyperactivity Disorder Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. South America Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Attention-Deficit Hyperactivity Disorder Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Stimulants
  • Non-stimulants
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • The Takeda Pharmaceutical Company Limited
  • Johnson & Johnson
  • Eli Lilly and Company
  • Pfizer Inc.
  • Supernus Pharmaceutical,Inc.
  • purdue Pharma L.P.
  • Novartis AG
  • Neos Therapeutics Inc.
  • Mallinckrodt Pharmaceuticals
  • Lupin Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Attention-Deficit Hyperactivity Disorder Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Attention-Deficit Hyperactivity Disorder Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Attention-Deficit Hyperactivity Disorder Treatment Market Dynamics
  1. 2.1 Attention-Deficit Hyperactivity Disorder Treatment Industry Trends
  2. 2.2 Attention-Deficit Hyperactivity Disorder Treatment Industry Drivers
  3. 2.3 Attention-Deficit Hyperactivity Disorder Treatment Industry Opportunities and Challenges
  4. 2.4 Attention-Deficit Hyperactivity Disorder Treatment Industry Restraints
3 Attention-Deficit Hyperactivity Disorder Treatment Market by Company
  1. 3.1 Global Attention-Deficit Hyperactivity Disorder Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Attention-Deficit Hyperactivity Disorder Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Attention-Deficit Hyperactivity Disorder Treatment Company Ranking (2024-2026)
  4. 3.4 Global Attention-Deficit Hyperactivity Disorder Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Attention-Deficit Hyperactivity Disorder Treatment Company Product Type and Application
  6. 3.6 Global Attention-Deficit Hyperactivity Disorder Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Attention-Deficit Hyperactivity Disorder Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Attention-Deficit Hyperactivity Disorder Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Attention-Deficit Hyperactivity Disorder Treatment Market by Type
  1. 4.1 Attention-Deficit Hyperactivity Disorder Treatment Type Introduction
  2. 4.1.1 Stimulants
  3. 4.1.2 Non-stimulants
  4. 4.2 Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Type
  5. 4.2.1 Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Type (2021-2032)
  7. 4.2.3 Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type (2021-2032)
5 Attention-Deficit Hyperactivity Disorder Treatment Market by Application
  1. 5.1 Attention-Deficit Hyperactivity Disorder Treatment Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Application
  6. 5.2.1 Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application (2021-2032)
6 Attention-Deficit Hyperactivity Disorder Treatment Regional Value Analysis
  1. 6.1 Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Attention-Deficit Hyperactivity Disorder Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Attention-Deficit Hyperactivity Disorder Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Attention-Deficit Hyperactivity Disorder Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Attention-Deficit Hyperactivity Disorder Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Attention-Deficit Hyperactivity Disorder Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Country, 2025 VS 2032
7 Attention-Deficit Hyperactivity Disorder Treatment Country-level Value Analysis
  1. 7.1 Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Attention-Deficit Hyperactivity Disorder Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Attention-Deficit Hyperactivity Disorder Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Attention-Deficit Hyperactivity Disorder Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 The Takeda Pharmaceutical Company Limited
  2. 8.1.1 The Takeda Pharmaceutical Company Limited Company Information
  3. 8.1.2 The Takeda Pharmaceutical Company Limited Business Overview
  4. 8.1.3 The Takeda Pharmaceutical Company Limited Attention-Deficit Hyperactivity Disorder Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 The Takeda Pharmaceutical Company Limited Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio
  6. 8.1.5 The Takeda Pharmaceutical Company Limited Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Attention-Deficit Hyperactivity Disorder Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Eli Lilly and Company
  14. 8.3.1 Eli Lilly and Company Company Information
  15. 8.3.2 Eli Lilly and Company Business Overview
  16. 8.3.3 Eli Lilly and Company Attention-Deficit Hyperactivity Disorder Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly and Company Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio
  18. 8.3.5 Eli Lilly and Company Recent Developments
  19. 8.4 Pfizer Inc.
  20. 8.4.1 Pfizer Inc. Company Information
  21. 8.4.2 Pfizer Inc. Business Overview
  22. 8.4.3 Pfizer Inc. Attention-Deficit Hyperactivity Disorder Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc. Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio
  24. 8.4.5 Pfizer Inc. Recent Developments
  25. 8.5 Supernus Pharmaceutical,Inc.
  26. 8.5.1 Supernus Pharmaceutical,Inc. Company Information
  27. 8.5.2 Supernus Pharmaceutical,Inc. Business Overview
  28. 8.5.3 Supernus Pharmaceutical,Inc. Attention-Deficit Hyperactivity Disorder Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Supernus Pharmaceutical,Inc. Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio
  30. 8.5.5 Supernus Pharmaceutical,Inc. Recent Developments
  31. 8.6 purdue Pharma L.P.
  32. 8.6.1 purdue Pharma L.P. Company Information
  33. 8.6.2 purdue Pharma L.P. Business Overview
  34. 8.6.3 purdue Pharma L.P. Attention-Deficit Hyperactivity Disorder Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 purdue Pharma L.P. Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio
  36. 8.6.5 purdue Pharma L.P. Recent Developments
  37. 8.7 Novartis AG
  38. 8.7.1 Novartis AG Company Information
  39. 8.7.2 Novartis AG Business Overview
  40. 8.7.3 Novartis AG Attention-Deficit Hyperactivity Disorder Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis AG Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio
  42. 8.7.5 Novartis AG Recent Developments
  43. 8.8 Neos Therapeutics Inc.
  44. 8.8.1 Neos Therapeutics Inc. Company Information
  45. 8.8.2 Neos Therapeutics Inc. Business Overview
  46. 8.8.3 Neos Therapeutics Inc. Attention-Deficit Hyperactivity Disorder Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Neos Therapeutics Inc. Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio
  48. 8.8.5 Neos Therapeutics Inc. Recent Developments
  49. 8.9 Mallinckrodt Pharmaceuticals
  50. 8.9.1 Mallinckrodt Pharmaceuticals Company Information
  51. 8.9.2 Mallinckrodt Pharmaceuticals Business Overview
  52. 8.9.3 Mallinckrodt Pharmaceuticals Attention-Deficit Hyperactivity Disorder Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mallinckrodt Pharmaceuticals Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio
  54. 8.9.5 Mallinckrodt Pharmaceuticals Recent Developments
  55. 8.10 Lupin Limited
  56. 8.10.1 Lupin Limited Company Information
  57. 8.10.2 Lupin Limited Business Overview
  58. 8.10.3 Lupin Limited Attention-Deficit Hyperactivity Disorder Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lupin Limited Attention-Deficit Hyperactivity Disorder Treatment Product Portfolio
  60. 8.10.5 Lupin Limited Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst